LIVA-HEALTHCARE
A leading provider of scalable digital health coaching in Europe, Liva Healthcare (“Liva”), launches new Scientific Advisory Board. Liva has attracted some of Europe’s most respected scientific leaders within chronic conditions and behaviour change psychology to join its global Advisory Board. The board will oversee the medical quality of the programmes and conduct the latest scientific research into Liva’s behavioural change model.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005646/en/
Liva is a health tech company that improve the lives of people at risk of, or living with, chronic conditions such as type 2 diabetes, obesity, and cardiovascular diseases by driving positive behavioural change. Liva recently announced a new funding round of EUR 24.5 million with the aim to expand its European operations. The Liva programmes are used by leading players in public healthcare, insurance and life science industries globally.
Through an app, Liva provides personal human coaching programmes to help people manage their condition and develop healthier habits that last. Liva’s combination of scalable health coaching focused on personal human relationships, with an intuitive and user-friendly interface, has proven to drive substantial clinical outcomes, and is particularly effective among traditionally hard to reach socio-economic groups.
Users on the programme living with obesity have an average sustained weight loss of 6,8kg during the first 9 months, 85% of users at high risk of developing type 2 diabetes reduce their HbA1c levels in 6 months, and 44% of users living with type 2 diabetes normalise their HbA1c level and achieve ‘control’ of their condition after 12 months on the programme (HbA1c level gets below 48 mmol/mol (6,5%).
The Advisory Board will be chaired by Liva’s Chief Medical Officer, MD, PhD, Carl J. Brandt, Postdoctoral researcher at the Research Unit for General Practice, University of Southern Denmark.
“We are proud to present a global Advisory Board of this calibre. With this board, Liva has managed to attract some of Europe’s top scientific leaders to oversee the medical and ethical quality of the Liva programmes, give input on study scope and design, and oversee the evidence-based nature of the Liva programmes,” says Dr. Brandt. “We have gathered multiple competences within our therapeutic and technological areas to guide decision-making and ensure science and research is the foundation for everything we do,” adds Dr. Brandt.
Joining Liva’s Advisory Board is Prof. Dr Lisette Van Gemert-Pijnen, Chair of Persuasive Health Technology at university of Twente, and Head of Centre for eHealth & Wellbeing Research.
“In our research at university of Twente and the Centre for eHealth & Wellbeing Research, we study how persuasive health technology can be applied to increase self-management of long-term chronic diseases, like diabetes,” says Prof. Gemert-Pijnen. “Liva Healthcare has demonstrated impressive proven clinical outcomes in chronic disease prevention and management, especially within obesity, prediabetes and type 2 diabetes, and that is why I have decided to join the Advisory Board.”
“I have been conducting research on the Dutch COVID-19 contact tracing app: CoronaMelder, and COVID-19 has taught us the importance of user-friendly, reliable and inclusive digital health tools. Generally, there has been a shift in acceptance of remote healthcare, and the need for credible digital solutions is now greater than ever. Fortunately, the Liva programmes have demonstrated how effective personalised, remote health solutions can be, and I am delighted to take a seat in this highly competent Advisory Board,” adds Prof. Gemert-Pijnen.
Additional Advisory Board members include:
- Prof. Timothy Skinner, Director of University department of Rural Health at La Trobe University, and Professor of Health Psychology at University of Copenhagen. Prof. Skinner has been responsible for developing several diabetes self-management support programmes, including DESMOND, the longest standing NHS training course for people with type 2 diabetes.
- Prof. Thorsten Lewalter, Head of Department of Cardiology, int. Klinikum München Süd, and Director of Department of Cardiology, Peter Osypka Heart Center. Prof. Lewalter is a renowned cardiology expert. He is co-editor of numerous professional journals and is considered one of the founders of modern therapy of cardiac arrhythmias.
- Stephanie Kaiser, Founder and Managing Director of the digital health platform Heartbeat Labs. Kaiser has more than 12 years’ experience in building and developing digital, consumer-oriented products. Since 2018, Kaiser has been a member of the Digital Council that advises the chancellor of Germany and the German government on the important matter of digitalisation.
- Prof. Åke Sjöholm, Associate Professor of Medicine at University of Gävle, Associate Professor at Karolinska Institute, Professor of University of South Alabama, and Associate Professor Diabetes at Region Gävleborg. Prof. Sjöholm is a prominent Swedish diabetes expert and has been listed as a noteworthy diabetes researcher by Marquis Who's Who.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005646/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
